{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:12:59Z","timestamp":1789017179502,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the impact of postoperative complications on long-term survival in patients with peritoneal metastasis (PM) arising from colorectal cancer (CRC) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with PM arising from CRC treated with CRS and HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. High-grade complications that occurred within 30\u2009days were defined as grade 3 to 4 events according to the Common Terminology Criteria for Adverse Events (CTCAE) classification. Univariate and multivariable Cox regression models for overall survival were created. Predictors of high-grade postoperative complications were evaluated with univariate and multivariate logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In all, 86 consecutive cases were included in this study. Forty-one patients (47.7%) developed postoperative complications, while 22 patients (25.6%) experienced high-grade complications. No mortality occurred during the postoperative period. The median survival of all patients was 25\u2009months, and the estimated 3-year overall survival (OS) rate was 35.0%. In the multivariable Cox regression analysis, a high peritoneal carcinomatosis index (PCI) score (HR, 1.07, 95% CI, 1.01\u20131.14;\n                      <jats:italic>P<\/jats:italic>\n                      =0.015) and grade 3\u20134 postoperative complications (HR, 1.86, 95% CI, 1.22\u20133.51;\n                      <jats:italic>P<\/jats:italic>\n                      =0.044) correlated with worse overall survival. High estimated blood loss (OR, 1.01, 95% CI, 1.01\u20131.02;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;\u20090.001) was identified as an independent risk factor for developing high-grade complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Careful patient selection, high levels of technical skill and improved perioperative management are crucial to ensure patient survival benefits after CRS+HIPEC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07756-7","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T14:03:18Z","timestamp":1610028198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Sicheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"6","key":"7756_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7756_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705.","journal-title":"Br J Surg"},{"issue":"11","key":"7756_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/ijc.25596","volume":"128","author":"VE Lemmens","year":"2011","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717\u201325.","journal-title":"Int J Cancer"},{"issue":"3","key":"7756_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PPO.0b013e3181a58d95","volume":"15","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15(3):216\u201324.","journal-title":"Cancer J"},{"issue":"12","key":"7756_CR5","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ejso.2018.07.003","volume":"44","author":"M Bushati","year":"2018","unstructured":"Bushati M, Rovers KP, Sommariva A, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the peritoneal surface oncology group international (PSOGI). Eur J Surg Oncol. 2018;44(12):1942\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"7756_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin PH, Mahteme H, Sp\u00e5ng N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155\u201362.","journal-title":"Eur J Cancer"},{"issue":"3","key":"7756_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"10","key":"7756_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"7756_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9 D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065\u201371.","journal-title":"Ann Surg"},{"key":"7756_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","volume":"36","author":"F Quenet","year":"2018","unstructured":"Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36:18.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7756_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1245\/s10434-015-4627-8","volume":"23","author":"M Faron","year":"2016","unstructured":"Faron M, Macovei R, Go\u00e9r\u00e9 D, et al. Linear relationship of peritoneal Cancer index and survival in patients with peritoneal metastases from colorectal Cancer. Ann Surg Oncol. 2016;23(1):114\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7756_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejso.2016.09.010","volume":"43","author":"G Lorimier","year":"2017","unstructured":"Lorimier G, Linot B, Paillocher N, et al. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 2017;43(1):150\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"7756_CR13","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1245\/s10434-018-6539-x","volume":"25","author":"NR Sluiter","year":"2018","unstructured":"Sluiter NR, Rovers KP, Salhi Y, et al. Metachronous peritoneal metastases after adjuvant chemotherapy are associated with poor outcome after Cytoreduction and HIPEC. Ann Surg Oncol. 2018;25(8):2347\u201356.","journal-title":"Ann Surg Oncol"},{"key":"7756_CR14","first-page":"1920276","volume":"2018","author":"A Sipok","year":"2018","unstructured":"Sipok A, Sardi A, Nieroda C, et al. Comparison of survival in patients with isolated peritoneal Carcinomatosis from colorectal Cancer treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276.","journal-title":"Int J Surg Oncol"},{"issue":"4","key":"7756_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10151-020-02159-z","volume":"24","author":"C Agalar","year":"2020","unstructured":"Agalar C, Sokmen S, Arslan C, et al. The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience. Tech Coloproctol. 2020;24(4):301\u20138.","journal-title":"Tech Coloproctol"},{"key":"7756_CR16","doi-asserted-by":"crossref","unstructured":"Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol, 2020, [published online ahead of print, 2020 Apr 1].","DOI":"10.1002\/jso.25920"},{"issue":"3","key":"7756_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/jcm9030748","volume":"9","author":"EW Beal","year":"2020","unstructured":"Beal EW, Suarez-Kelly LP, Kimbrough CW, et al. Impact of Neoadjuvant chemotherapy on the outcomes of Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748.","journal-title":"J Clin Med"},{"issue":"1","key":"7756_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12957-020-1784-4","volume":"18","author":"JSM Wong","year":"2020","unstructured":"Wong JSM, Tan GHC, Chia CS, et al. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2020;18(1):10.","journal-title":"World J Surg Oncol"},{"issue":"7","key":"7756_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/DCR.0000000000000149","volume":"57","author":"D Baratti","year":"2014","unstructured":"Baratti D, Kusamura S, Iusco D, et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57(7):858\u201368.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"7756_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1245\/s10434-015-4914-4","volume":"23","author":"M Maillet","year":"2016","unstructured":"Maillet M, Glehen O, Lambert J, et al. Early postoperative chemotherapy after complete Cytoreduction and Hyperthermic Intraperitoneal chemotherapy for isolated peritoneal Carcinomatosis of Colon Cancer: a multicenter study. Ann. Surg Oncol. 2016;23(3):863\u20139.","journal-title":"Surg Oncol"},{"issue":"2","key":"7756_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jso.24290","volume":"114","author":"IS Froysnes","year":"2016","unstructured":"Froysnes IS, Larsen SG, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114(2):222\u20137.","journal-title":"J Surg Oncol"},{"issue":"2","key":"7756_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amjsurg.2016.03.008","volume":"213","author":"D Massalou","year":"2017","unstructured":"Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213(2):377.","journal-title":"Am J Surg"},{"issue":"2","key":"7756_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.24632","volume":"116","author":"L Lee","year":"2017","unstructured":"Lee L, Alie-Cusson F, Dub\u00e9 P, et al. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Surg Oncol. 2017;116(2):236\u201343.","journal-title":"J Surg Oncol"},{"issue":"4","key":"7756_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jso.24911","volume":"117","author":"MA Kozman","year":"2018","unstructured":"Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725\u20136.","journal-title":"J Surg Oncol"},{"issue":"10","key":"7756_CR25","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s12094-018-1857-9","volume":"20","author":"M Tonello","year":"2018","unstructured":"Tonello M, Ortega-Perez G, Alonso-Casado O, et al. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases. Clin Transl Oncol. 2018;20(10):1268\u201373.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"7756_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12957-019-1602-z","volume":"17","author":"L Solaini","year":"2019","unstructured":"Solaini L, D'Acapito F, Passardi A, et al. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study[J]. World J Surg Oncol. 2019;17(1):58.","journal-title":"World J Surg Oncol"},{"issue":"16","key":"7756_CR27","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7756_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol"},{"key":"7756_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"7756_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9","volume":"92","author":"D Elias","year":"2001","unstructured":"Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71\u20136.","journal-title":"Cancer"},{"issue":"1","key":"7756_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29\u201342.","journal-title":"Ann Surg"},{"issue":"2","key":"7756_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","volume":"16","author":"JL Koh","year":"2009","unstructured":"Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327\u201333.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"7756_CR33","first-page":"461","volume":"42","author":"S Hamashige","year":"2008","unstructured":"Hamashige S, Arquilla ER. Common terminology criteria for adverse events v3.0 (CTCAE). Principles and Practice of Clinical Trial Medicine. 2008;42(4):461\u2013533.","journal-title":"Principles and Practice of Clinical Trial Medicine"},{"issue":"6","key":"7756_CR34","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900\u20137.","journal-title":"Ann Surg"},{"issue":"5","key":"7756_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10147-019-01609-5","volume":"25","author":"JW Tan","year":"2020","unstructured":"Tan JW, Tan GHC, Ng WY, et al. High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Clin Oncol. 2020;25(5):984\u201394.","journal-title":"Int J Clin Oncol"},{"key":"7756_CR36","doi-asserted-by":"crossref","unstructured":"Narasimhan V, Tan S, Kong J, et al. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Colorectal Dis. 2020;22(11):1482-95.","DOI":"10.1111\/codi.15003"},{"issue":"1","key":"7756_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13304-019-00691-8","volume":"72","author":"A Macr\u00ec","year":"2020","unstructured":"Macr\u00ec A, Arcoraci V, Belgrano V, et al. Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of Colo-rectal carcinomatosis: a multicentric study. Updat Surg. 2020;72(1):163\u201370.","journal-title":"Updat Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07756-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T15:09:38Z","timestamp":1610291378000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07756-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7756"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07756-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-92582\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"1 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved this study. Prior written informed consent was obtained from all study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}